A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2002
10/31/2002	WO2001056601A9 Low dose haptenized tumor cell and tumor cell extract immunotherapy
10/31/2002	WO2001054701A9 Vaccination of hiv infected persons following highly active antiretroviral therapy
10/31/2002	WO2001051633A9 Compositions and methods for the therapy and diagnosis of prostate cancer
10/31/2002	WO2001047962A8 Attenuated microorganisms for the treatment of infection
10/31/2002	US20020162129 Prevention and treatment of alzheimer's disease
10/31/2002	US20020162123 For therapy of tumors
10/31/2002	US20020161218 For immunizing
10/31/2002	US20020161212 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
10/31/2002	US20020161201 For use in cancer diagnosis and therapy
10/31/2002	US20020161200 For therapy
10/31/2002	US20020161192 Helicobacter pylori live vaccine
10/31/2002	US20020161191 Novel Imidazoline receptor homologs
10/31/2002	US20020161190 Method of identifying cells expressing a protein having pre-B cell growth-supporting ability
10/31/2002	US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002	US20020160980 Method of treating hepatitis delta virus infection
10/31/2002	US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002	US20020160959 Therapeutic compounds for ovarian cancer
10/31/2002	US20020160957 Treating tumors
10/31/2002	US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002	US20020160484 Central nervous system disorders therapy; genetic engineering
10/31/2002	US20020160477 CAF1-related protein
10/31/2002	US20020160456 Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
10/31/2002	US20020160447 Ups (ugc)
10/31/2002	US20020160433 Diagnosis of urogenital disorders
10/31/2002	US20020160387 Compositions and methods relating to ovary specific genes and proteins
10/31/2002	US20020160365 Compositions and methods for the early diagnosis of ovarian cancer
10/31/2002	US20020160359 Stabilizing diluent for polypeptides and antigens
10/31/2002	US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns
10/31/2002	US20020160022 Comprising viable wild type sporulated oocysts of protozoa known to cause coccidiosis, wherein composition is sterile and contains 10,000 oocysts per milliliter and less than 0.8% by weight of alkali metal permanganate
10/31/2002	US20020160021 Carrier group coupled to an oligosaccharide obtained from a lipoglycan found on surface of an eukaryote, the composition being administered in an amount sufficient to elicit a protective immune response against the eukaryotic parasite
10/31/2002	US20020160020 Enterohemorrhagic escherichia coli vaccine
10/31/2002	US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002	US20020160018 For inducing in a bovine host an immunological response against bovine respiratory syncytial virus or bovine viral diarrhea virus
10/31/2002	US20020160017 Malaria vaccine
10/31/2002	US20020160016 Modified surface antigen
10/31/2002	US20020160014 Cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells
10/31/2002	US20020160012 Vaccine chip technology exploiting immunostimulating fragment of TGF-BETA
10/31/2002	US20020160011 Adjuvant compositions for vaccines
10/31/2002	US20020160010 Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
10/31/2002	US20020160009 For treatment of disseminated candidiasis due to infection by C. albicans; composition includes phosphomannan of C. albicans
10/31/2002	US20020160006 Methods of treating lymphoma and leukemia
10/31/2002	US20020160003 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
10/31/2002	US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002	US20020159999 Administering donor peripheral blood progenitor cells to recipient and administering a non-chronic course of an immunosuppressant, e.g., cyclosporine
10/31/2002	US20020159997 For passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S.aureus and S.epidermidis
10/31/2002	US20020159996 Use of CD23 antagonists for the treatment of neoplastic disorders
10/31/2002	US20020159979 Adeno- associated virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to a promoter and polyadenylation sequences
10/31/2002	US20020159971 Methods and compositions for preventing and treating neutrophil-mediated diseases
10/31/2002	US20020159954 Aerodynamically light poly((p-carboxyphenoxy)-hexane anhydride) particles
10/31/2002	DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002	DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002	DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002	CA2483507A1 Enzyme and snp marker for disease
10/31/2002	CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002	CA2445179A1 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002	CA2445168A1 Human timp-1 antibodies
10/31/2002	CA2444883A1 Microprojection array having a beneficial agent containing coating
10/31/2002	CA2444747A1 Smallpox vaccine
10/31/2002	CA2444691A1 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002	CA2444675A1 Secreted proteins
10/31/2002	CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002	CA2444006A1 Expression of core-glycosylated hcv envelope proteins in yeast
10/31/2002	CA2443781A1 Core-glycosylated hcv envelope proteins
10/31/2002	CA2443740A1 Constructs and methods for expression of recombinant hcv envelope proteins
10/31/2002	CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	CA2441540A1 Replikin peptides and uses thereof
10/31/2002	CA2438833A1 Lactic acid bacteria as agents for treating and preventing allergy
10/30/2002	EP1253201A2 Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor
10/30/2002	EP1253197A1 Attenuated recombinant rabies virus and live vaccines thereof
10/30/2002	EP1252319A2 Combinatorial protein domains
10/30/2002	EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
10/30/2002	EP1252300A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
10/30/2002	EP1252294A2 Compounds and methods for prevention and treatment of her-2/neu associated malignancies
10/30/2002	EP1252192A2 Enhancing the circulating half-life of antibody-based fusion proteins
10/30/2002	EP1252183A2 Method for reducing the immunogenicity of heterologous proteins by elimination of t-cell epitopes
10/30/2002	EP1252182A1 PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
10/30/2002	EP1252180A2 Virulence genes, proteins, and their use
10/30/2002	EP1252162A1 Alpha v integrin receptor antagonists
10/30/2002	EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
10/30/2002	EP1251872A1 Compositions and methods for treating cell proliferation disorders
10/30/2002	EP1251871A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
10/30/2002	EP1251870A2 Novel use
10/30/2002	EP1251869A2 Compositions and method for preventing reactogenicity associated with administration of immunogenic live rotavirus compositions
10/30/2002	EP1251835A2 Closure of bacterial ghosts
10/30/2002	EP0862740B1 Oncogene fusion protein peptide vaccines
10/30/2002	EP0699076B1 Otitis media vaccine
10/30/2002	CN1377415A 疫苗组合物 Vaccine composition
10/30/2002	CN1377411A BASB 119 polypeptide and polynucleotide from noraxella catarrhalis
10/30/2002	CN1377410A Nucleic acids and proteins from group B streptoccus
10/30/2002	CN1377408A The PRV-1 gene and use thereof
10/30/2002	CN1377369A Vaccine antigens of moraxella
10/30/2002	CN1377280A Diagnosis and treatment of neuroectodermal tumors
10/30/2002	CN1377279A Use of soluble cosmetimulatory molecules to enhance immune responses
10/30/2002	CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002	CN1377274A Treatment of chronic viral infections with i (M. Vannae)
10/30/2002	CN1377257A Hybrid matrices and hybrid matrix mixtures
10/30/2002	CA2383819A1 Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
10/29/2002	US6472520 Rat PEG-3 promoter
10/29/2002	US6472511 Stimulation of an immune response with antibodies labeled with the α-galactosyl epitope
10/29/2002	US6472506 Polysaccharide-peptide-conjugates

1 ... 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 ... 1823